Front. Physiol. Frontiers in Physiology Front. Physiol. 1664-042X Frontiers Media S.A. 1092217 10.3389/fphys.2022.1092217 Physiology Erratum Erratum: Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential Frontiers Production Office 10.3389/fphys.2022.1092217 Frontiers Production Office * Frontiers Media SA, Lausanne, Switzerland *Correspondence: Frontiers Production Office, production.office@frontiersin.org

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

This article was submitted to Cell Physiology, a section of the journal Frontiers in Physiology

 21 11 2022 2022 13 1092217 07 11 2022 07 11 2022 Copyright © 2022 Frontiers Production Office. 2022 Frontiers Production Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 An Erratum on Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential by Rossetti T, Ferreira J, Ghanem L, Buck H, Steegborn C, Myers RW, Meinke PT, Levin LR and Buck J (2022). Front. Physiol. 13:1013845. doi: 10.3389/fphys.2022.1013845 soluble adenylyl cyclase male contraceptive residence time drug development picomolar potency binding kinetics lead optimization SPR

Due to a production error, Figure 4 was a duplication of Figure 3. The correct Figure 4 is shown below

In Vitro Jump Dilution Assay for Determining sAC Inhibitor Residence Times. (A) Schematic diagram of the jump dilution assay (figure adapted from BellBrook Labs “A Guide to Measuring Drug Target Residence Times with Biochemical Assays”). (B) In vitro jump dilution curves of indicated inhibitors. All assays were done at 30°C in the presence of 2 mM ATP, 10 mM Mn2+ and ∼0.25 nM of purified recombinant human sAC protein. Following a 100-fold dilution, sAC cyclase activity was measured every 6 min for 60 min. Data is normalized to respective DMSO-treated controls and is shown as mean ± SEM (n ≥ 4).

The publisher apologizes for the mistake. The original article has been updated.